Medication classes
Steroid articles covering flare control, tapering, side effects, safety, and alternatives in IBD care. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 1 of 2 · 80 articles
A formulation that targets and sustains budesonide release in the intestine could improve local anti-inflammatory effects and reduce systemic exposure compared with standard oral formulations. If translational studies...
People hospitalized with acute severe ulcerative colitis face a high risk of steroid failure and need for rescue therapy or colectomy. This trial explores whether adding the JAK inhibitor tofacitinib to corticosteroids...
Overlap of EoE and IBD appears uncommon but more frequent than in the general population and is linked to more allergic disease and higher steroid exposure without clearer increases in esophageal scarring. That may...
For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need...
The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.
Children with newly diagnosed IBD are increasingly started on advanced therapies early after diagnosis and are receiving fewer corticosteroids.
Researchers are exploring ways to deliver steroids like budesonide more precisely to the intestine while avoiding stomach leakage and sudden drug release. If translated to humans, such a formulation could improve local...
A pediatric trial of budesonide rectal foam could provide evidence about a locally acting steroid option for children with distal ulcerative colitis. Trial results may affect treatment choices for pediatric distal...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.
Systemic glucocorticoids used for UC can cause bone loss; identifying early, noninvasive markers could let clinicians detect steroid-induced osteoporosis sooner and intervene to reduce fracture risk.
The analysis compares rescue drugs used when severe ulcerative colitis doesn't respond to IV steroids — a high-stakes situation where avoiding colectomy matters.
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.
This study addresses whether continuing advanced biologic therapies around abdominal surgery raises short-term postoperative risks—important for IBD patients and clinicians planning surgery.
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...
Severe UC flares can produce extreme but reversible hyperglycemia that may look like new-onset diabetes, so patients and clinicians should monitor and re-evaluate glucose over time rather than assuming a permanent...
Dexamethasone is a systemic corticosteroid with an official label that still includes short‑term use to "tide the patient over a critical period" in Crohn's disease (regional enteritis) and ulcerative colitis.
Trends in treatments for children with IBD can affect hospitalization and surgical needs. Noting rising use of biologics (infliximab) alongside fewer hospitalizations may be important for families and clinicians tracking...
This is the official FDA label text for dexamethasone, so it clarifies approved uses and gives practical dosing and tapering guidance. It explicitly names "regional enteritis and ulcerative colitis," which matters to...
This FDA label page documents official prescribing information for SOLU-CORTEF (hydrocortisone), including explicit gastrointestinal/IBD indications (regional enteritis and ulcerative colitis) and IV/IM dosing guidance.
Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.
This study maps cell-level signatures in newly diagnosed pediatric Crohn’s and links them to later severity and responses to anti-TNF treatment, which could help predict which children will respond to biologic therapy...
The study outlines a strategy to target corticosteroids to inflamed intestinal tissue by exploiting PLA2 overexpression, which could reduce systemic steroid side effects if the approach translates to biological models...
Corticosteroid use during IBD treatment periods was associated with higher rates of serious infections across drug classes and age groups, which may affect decisions about steroid use and infection-prevention planning.
Prednisone is commonly used short-term in IBD flares; an FDA label update clarifies approved uses and dosing considerations that affect how clinicians prescribe it and how patients should take and stop the drug.
This study suggests that using 5‑ASA drugs early in children with Crohn’s disease was common but linked to more steroid use, delayed biologic treatment, and lower biologic durability — outcomes that matter for long‑term...
CVID-related enteropathy can resemble celiac disease or IBD, carries high morbidity and mortality, and often does not respond to standard immunoglobulin therapy — patients and clinicians need awareness of its distinct...
People receiving immune checkpoint inhibitors who develop colitis may face different risks of needing stronger immunosuppression depending on the ICI drug class. Understanding which features predict escalation could...
The article reviews current and emerging IBD treatments and the biological reasons they may work — useful for patients wanting to understand treatment options and future directions. It highlights therapies beyond...
The FDA label confirms triamcinolone acetonide injectable suspension is indicated for short-term use to manage flares in regional enteritis (Crohn’s disease) and ulcerative colitis and summarizes important safety and...
Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.
This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...
This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...
This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.
For people hospitalized with acute severe ulcerative colitis, starting a JAK inhibitor together with IV steroids right away (rather than waiting for steroids to fail) could potentially control inflammation sooner and...
The review links gut microbiota changes and mucosal immune responses across IBD and IgA nephropathy, suggesting that gut dysbiosis may contribute to systemic immune-driven disease.
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
Crohn's-like disease of the pouch is a meaningful complication after IPAA that can impair quality of life and risk pouch failure; knowing which drug classes show promise for specific pouch phenotypes can guide...
Most people with IBD can have children safely with modern treatments and planning; uncontrolled disease poses greater risks to pregnancy than continuing most IBD medications. Planning and specialist input before...
This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.
Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...
